Ceramides and Glucosylceramides Are Independent Antagonists of Insulin Signaling
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Inhibitors of sphingolipid synthesis protect mice from diet induced-insulin resistance, and sphingolipids such as ceramides and glucosylated-ceramides (e.g., GM3) are putative nutritional intermediates linking obesity to diabetes risk. Herein we investigated the role of each of these sphingolipids in muscle and adipose tissue and conclude that they are independent and separable antagonists of insulin signaling. Of particular note, ceramides antagonize insulin signaling in both myotubes and adipocytes, whereas glucosyceramides are only efficacious in adipocytes: 1) In myotubes exposed to saturated fats, inhibitors of enzymes required for ceramide synthesis enhance insulin signaling, but those targeting glucosylceramide synthase have no effect. 2) Exogenous ceramides antagonize insulin signaling in myotubes, whereas ganglioside precursors do not. 3) Overexpression of glucosylceramide synthase in myotubes induces glucosylceramide but enhances insulin signaling. In contrast, glucosylated ceramides have profound effects in adipocytes. For example, either ganglioside addition or human glucosylceramide synthase overexpression suppresses insulin signaling in adipocytes. These data have important mechanistic implications for understanding how these sphingolipids contribute to energy sensing and the disruption of anabolism under conditions of nutrient oversupply.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Holland, W. L., Brozinick, J. T., Wang, L.-P., Hawkins, E. D., Sargent, K. M., Liu, Y., Narra, K., Hoehn, K. L., Knotts, T. A., Siesky, A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.01.002 · Cited by 1,232 · cited 1×
“Pharmacological inhibitors of serine palmitoyltransferase (51), dihydroceramide desaturase (31), and glucosylceramide synthase (11, 12) have an overlapping, broad spectrum of beneficial metabolic effects in rodents.”
Self-citationReceptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
Holland, W. L., Miller, R. A., Wang, Z. V., Sun, K., Barth, B. M., Bui, H. H., Davis, K. E., Bikman, B. T., Halberg, N., Rutkowski, J. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2277 · Cited by 892
Self-citationHolland, W. L., Bikman, B. T., Wang, L.-P., Yuguang, G., Sargent, K. M., Bulchand, S., Knotts, T. A., Shui, G., Clegg, D. J., Wenk, M. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43378 · Cited by 705 · cited 1×
“, inflammatory molecules and adipokines) (3, 52) will require close attention to details and experimental limitations.”
Self-citationChavez, J. A., Knotts, T. A., Wang, L.-P., Li, G., Dobrowsky, R. T., Florant, G. L., & Summers, S. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212307200 · Cited by 617 · cited 2×
“Palmitate-induced Insulin Resistance Is Unaffected by GCS Inhibition—The data showing roles for GSLs in rodent models of metabolic disease have relied on next generation GCS inhibitors that, unlike the compound used in our prior study (25), do not promote ceramide accumulation (19).”
Self-citationEnhanced insulin sensitivity in mice lacking ganglioside GM3
Yamashita, T., Hashiramoto, A., Haluzik, M., Mizukami, H., Beck, S., Norton, A., Kono, M., Tsuji, S., Daniotti, J. L., Werth, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0635898100 · Cited by 531
Chavez, J. A., & Summers, S. A. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.020 · Cited by 498
Self-citationSkeletal Muscle Triglycerides, Diacylglycerols, and Ceramides in Insulin Resistance
Amati, F., Dubé, J. J., Alvarez-Carnero, E., Edreira, M. M., Chomentowski, P., Coen, P. M., Switzer, G. E., Bickel, P. E., Stefanovic-Racic, M., Toledo, F. G. S., et al. (2011) · Diabetes · doi:10.2337/db10-1221 · Cited by 395
Ganglioside GM3 Participates in the Pathological Conditions of Insulin Resistance
Tagami, S., Inokuchi, J.-I., Kabayama, K., Yoshimura, H., Kitamura, F., Uemura, S., Ogawa, C., Ishii, A., Saito, M., Ohtsuka, Y., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m103705200 · Cited by 355 · cited 2×
“An insulin-resistant adipocyte model was established as described previously with minor modifications (22).”
POWELL, D. J., TURBAN, S., GRAY, A., HAJDUCH, E., & HUNDAL, H. S. (2004) · Biochemical Journal · doi:10.1042/bj20040139 · Cited by 267
Kabayama, K. (2004) · Glycobiology · doi:10.1093/glycob/cwh135 · Cited by 155
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Sphingolipids and their metabolism in physiology and disease
Hannun, Y. A., & Obeid, L. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.107 · Cited by 2,051
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Ceramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.006 · Cited by 616
Self-citationThe Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570
“brane components and biologically active lipids that have been implicated in insulin resistance, oxidative stress and inflammation [15].”
BackgroundSphingolipids and phospholipids in insulin resistance and related metabolic disorders
Meikle, P. J., & Summers, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.169 · Cited by 423
Self-citationCeramides in Metabolism: Key Lipotoxic Players
Chaurasia, B., & Summers, S. A. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093815 · Cited by 343
Self-citationQuinville, B. M., Deschenes, N. M., Ryckman, A. E., & Walia, J. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115793 · Cited by 343
Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Funcke, J.-B., & Scherer, P. E. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r094060 · Cited by 327
Li, R.-Y., Qin, Q., Yang, H.-C., Wang, Y.-Y., Mi, Y.-X., Yin, Y.-S., Wang, M., Yu, C.-J., & Tang, Y. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00542-y · Cited by 204
Glycosphingolipids and Neuroinflammation in Parkinson’s Disease
Belarbi, K., Cuvelier, E., Bonte, M.-A., Desplanque, M., Gressier, B., Devos, D., & Chartier-Harlin, M.-C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00408-1 · Cited by 155
Kitessa, S., & Abeywardena, M. (2016) · Nutrients · doi:10.3390/nu8080466 · Cited by 98
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94
“Ceramides are bioactive lipid metabolites, released from membrane sphingomyelin by sphingomyelinases, implicated in insulin resistance, inflammation, oxidative stress, and cell death.(77) A de novo pathway of ceramide synthesis also occurs at the ER via the enzyme serine palmitoyltransferase 1 activation.”
BackgroundLipid-mediated muscle insulin resistance: different fat, different pathways?
Ritter, O., Jelenik, T., & Roden, M. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1310-2 · Cited by 74
“However, in vitro studies suggest that GM3 does not induce IR in myocytes [43].”
BackgroundLipotoxicity, aging, and muscle contractility: does fiber type matter?
Carter, C. S., Justice, J. N., & Thompson, L. (2019) · GeroScience · doi:10.1007/s11357-019-00077-z · Cited by 66
Gessner, D. K., Winkler, A., Koch, C., Dusel, G., Liebisch, G., Ringseis, R., & Eder, K. (2017) · BMC Genomics · doi:10.1186/s12864-017-3638-1 · Cited by 39
Kwon, O. S., Nelson, D. S., Barrows, K. M., O'Connell, R. M., & Drummond, M. J. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00253.2016 · Cited by 24
“The Summers laboratory (11) has elegantly showed that glucosylceramides impaired insulin sensitivity by accumulating in WT TLR4-/0 1000 2000 3000 4000”
Method
Metadata
- Authors
- Chavez, J. A., Siddique, M. M., Wang, S. T., Ching, J., Shayman, J. A., & Summers, S. A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 289
- Issue
- 2
- Pages
- 723-734
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2039450150
- Cited by
- 147
- References
- 11
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.